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The Coactivator p300 Directly Acetylates the
Forkhead Transcription Factor Foxo1 and
Stimulates Foxo1-Induced Transcription
Vale´rie Perrot and Matthew M. Rechler
Growth and Development Section, Diabetes Branch, National Institute of Diabetes and Digestive and
Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892
The FOXO (Forkhead box class O) subgroup of
forkhead transcription factors controls the expres-
sion of many genes involved in fundamental cellu-
lar processes. Until recently, studies conducted on
posttranslational modifications of Forkhead pro-
teins were restricted to their phosphorylation. In
this report, we show that the coactivator p300 di-
rectly acetylates lysines in the carboxyl-terminal
region of Foxo1 in vivo and in vitro, and potently
stimulates Foxo1-induced transcription of IGF-
binding protein-1 in transient transfection experi-
ments. The intrinsic acetyltransferase activity of
p300 is required for both activities. Our results sug-
gest that acetylation of Foxo1 by p300 is respon-
sible, at least in part, for its increased transactiva-
tion potency, although acetylation of histones
cannot be excluded. Insulin, the major negative
regulator of Foxo1-stimulated transcription, po-
tently enhances p300 acetylation of Foxo1. Three
consensus protein kinase B/Akt phosphorylation
sites whose phosphorylation is stimulated by insu-
lin are required for insulin-induced acetylation of
Foxo1. In contrast to its importance in regulating
the transcriptional activity of Foxo1 in the absence
of insulin, acetylation plays only a minor role com-
pared with phosphorylation in insulin inhibition of
Foxo1 transcriptional activity. (Molecular Endocri-
nology 19: 2283–2298, 2005)
THE HIGHLY CONSERVED subfamily of Forkheadbox class O (FOXO) transcription factors (1, 2) was
initially identified at chromosomal translocations in
several human tumors (3–6). Members of the FOXO
subfamily include FOXO1, FOXO3a (7), FOXO4 (4, 5),
and FOXO6 (8). A closely related ortholog of FOXO1,
Daf-16, is expressed in Caenorhabditis elegans (9, 10).
The FOXO proteins regulate the transcription of genes
involved in key cellular processes such as cell cycle
progression, apoptosis, DNA repair, response to oxi-
dative stress, differentiation, and glucose metabolism
(reviewed in Refs. 11–16). They contain a highly con-
served central DNA binding domain (the Forkhead
Box) that binds to a FOXO response element (5-TT-
GTTTAC-3) located in the promoter of their target
genes (17, 18) and a carboxyl-terminal transactivation
domain (3, 19, 20). They also share three consensus
phosphorylation sites for serine/threonine protein ki-
nase B (PKB)/Akt (21). Insulin (22), as well as cytokines
and growth factors (23–26), inhibit FOXO-stimulated
transcription by activating a phosphatidylinositol 3-ki-
nase-PKB/Akt pathway (27, 28). PKB/Akt-mediated
phosphorylation of Foxo1 at consensus sites located
at Thr24, Ser253, and Ser316 (29) greatly reduces insulin
inhibition of target gene transcription and triggers the
export of Foxo1 from the nucleus (23, 30–32). In ad-
dition to PKB/Akt, serum and glucocorticoid-inducible
kinase (33) and inhibitor of nuclear factor-B kinase
(34) also induce cytoplasmic redistribution and tran-
scription inhibition by phosphorylating FOXO proteins.
Whereas the role of phosphorylation in the regula-
tion of FOXO activity has been extensively character-
ized, the importance of other posttranslational modi-
fications of the FOXO proteins such as ubiquination
(34–36) and acetylation (37–41) has only recently
emerged. Ubiquitination of phosphorylated FOXO pro-
teins targets them for proteosomal degradation,
whereas the effect of acetylation of FOXO proteins on
their transcriptional activity remains to be resolved.
The possibility that FOXO1 might be acetylated was
first suggested by the observation of Nasrin et al. (42),
showing that the adenoviral oncoprotein E1A inhibited
transcription stimulated by Daf-16 or FOXO1. E1A
might act by inhibiting binding of the FOXO proteins to
the closely related coactivators, p300 and CBP
[cAMP-responsive element-binding protein (CREB)-
binding protein] (43–45). p300 and CBP possess in-
trinsic acetyltransferase activity (46, 47), which en-
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ables them to regulate transcription by acetylating
histones and a growing list of transcription factors (48,
49). Indeed, while this study was in progress, several
reports have appeared showing that p300/CBP can
acetylate members of the FOXO subfamily (37, 38, 40,
41).
The functional implications of FOXO acetylation by
p300/CBP have not been studied extensively, and the
results obtained have been conflicting. Acetylation by
CBP inhibited the transcriptional activity of FOXO4
(38, 41), whereas acetylation by p300 stimulated the
transcriptional activity of FOXO3a (40). The present
study was undertaken to determine directly the effect
of p300 on Foxo1-stimulated transcription of the IGF-
binding protein-1 (IGFBP-1) promoter in the absence
and presence of insulin, and to determine whether
acetylation of Foxo1 by p300 was involved in its reg-
ulation of transcription. We demonstrate that the co-
activator p300 directly acetylates Foxo1 in vivo and in
vitro, and that p300 markedly increases Foxo1-stimu-
lated IGFBP-1 transcription when its acetyltransferase
activity is intact, suggesting that acetylation of Foxo1
by p300 may contribute to the enhancement of Foxo1-
stimulated transactivation. We also observed that in-
sulin potently enhances Foxo1 acetylation by p300
and that phosphorylation of the PKB/Akt sites is nec-
essary for insulin-dependent acetylation. Acetylation
of Foxo1 is an important regulator of Foxo1 transcrip-
tional activity in the absence of insulin but plays a
much less important role than phosphorylation in in-
sulin inhibition of Foxo1 transcriptional activity.
RESULTS
p300 Acetyltransferase Activity Is Required for
Acetylation of Foxo1 in Vivo
In light of the previous observation that CBP binds to
FOXO1 and Daf-16 (42), we first examined whether the
related coactivator p300 could acetylate Foxo1 when
the two proteins were coexpressed. Immunoblot anal-
ysis using an antibody specific for acetyl-lysine dem-
onstrated p300-dependent acetylation of Foxo1 in hu-
man embryonic kidney (HEK)-293T cells (Fig. 1A).
Foxo1 proteins remained unacetylated in the absence
of p300. Foxo1 acetylation also was observed in H4IIE
rat hepatoma cells (Fig. 1B), indicating that this post-
translational modification is not cell type specific.
Moreover, acetylation of Foxo1 by p300 depends on
the acetyltransferase activity of the coactivator protein
because an acetylase-deficient p300 point mutant
(p300-DY) (50) failed to induce Foxo1 acetylation (Fig.
1C). Our results corroborate the recent reports show-
ing that FOXO proteins can be acetylated (37–41) and
further show that p300 acetyltransferase activity is
required for Foxo1 acetylation.
p300 Stabilizes Foxo1 Protein in an
Acetyltransferase-Independent Manner
In addition to acetylating Foxo1, p300 appeared to
increase its abundance in comparison with cells ex-
pressing the vector control (Fig. 1A). The fact that
Foxo1 protein levels were increased to a comparable
extent in cells expressing either wild-type p300 or the
p300-DY mutant (Fig. 1C) suggested that the up-reg-
ulation of Foxo1 by p300 was unrelated to its acety-
lation. This was demonstrated by monitoring the dis-
appearance of the forkhead protein in cells
overexpressing wild-type (Fig. 2A) or mutant (Fig. 2B)
p300 when de novo protein synthesis was inhibited
with cycloheximide. As seen in Fig. 2, coexpression of
either wild-type or mutant p300 prolonged the half-life
of Foxo1 protein. Because Foxo1 is not acetylated by
p300-DY, these results indicate that p300 stabilizes
Foxo1 protein in an acetyltransferase-independent
manner.
p300 Interacts with and Directly Acetylates
Foxo1 Protein
The previous results suggested that p300 might di-
rectly acetylate Foxo1. To test this hypothesis, we first
examined whether the two proteins interacted physi-
cally using in vitro glutathione-S-transferase (GST)
pull-down assays (Fig. 3A). Lysates prepared from
HEK-293T cells overexpressing p300 were tested for
interactions with bacterially expressed GST control or
GST-fused FOXO1. The results shown in Fig. 3A indi-
cated that FLAG-p300 was specifically pulled down by
interaction with GST-FOXO1 but not by GST alone,
demonstrating that the two proteins can interact in
vitro. Endogenous Foxo1 also binds to p300. It was
detected in lysates of HEK-293T cells after immuno-
precipitation with antibody to p300 (Fig. 3B).
To confirm that p300 interacts with Foxo1 in vivo
and to delineate the region in Foxo1 involved in this
interaction, HEK-293T cells were transfected with
FLAG-p300 and full-length Foxo1 protein or its car-
boxyl-terminal region (Foxo1 208–652). Cell lysates
immunoprecipitated with antibodies against tagged-
Foxo1 proteins and subjected to Western blotting us-
ing antibody against FLAG-tagged p300 confirmed the
results observed in Fig. 3A and further demonstrated
that p300 was able to interact with the carboxyl-ter-
minal region of Foxo1 (Fig. 3C). Similar results were
obtained with p300-DY (Fig. 3D), indicating that the
acetyltransferase-deficient mutant can bind to Foxo1
and stabilize it but cannot acetylate it.
We next established that p300 can directly acetylate
Foxo1 by performing in vitro acetylation assays. Re-
combinant His6-tagged full-length p300 protein (gra-
ciously purified and provided by T. P. Yao and C. H.
Lai, Duke University, Durham, NC) was incubated with
GST-fused Foxo1 proteins in the presence of
[1-14C]acetyl-coenzyme A (CoA) (Fig. 4). As expected,
histones were strongly acetylated by p300. His6-
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tagged p300 protein directly acetylated GST-Foxo1
1–652 but not its amino-terminal region encompassing
amino acids 1–207 or the GST protein alone. These
data indicate that Foxo1 itself is a specific target of
p300 acetyltransferase activity and that the acetylation
site(s) is (are) located exclusively in the carboxyl-ter-
minal region of Foxo1.
p300 Increases Foxo1-Stimulated Transcription in
an Acetyltransferase-Dependent Manner
To examine the effect of p300 on the transcriptional
responses induced by Foxo1, transient transfection
assays were performed using an IGFBP-1 promoter-
luciferase reporter bearing two copies of a FOXO re-
sponse element. In agreement with the observation of
Nasrin et al. (42), overexpression of the adenovirus
E1A protein, which can competitively inhibit the bind-
ing of transcription factors to p300/CBP and thereby
inhibit transcriptional coactivation (43, 51), strongly
reduced basal expression of the IGFBP-1 promoter
(data not shown). E1A inhibition was overcome by
overexpression of p300 (data not shown). These re-
sults suggest that p300/CBP or an endogenous coac-
tivator homolog may be involved in the stimulation of
IGFBP-1 promoter activity by Foxo1.
Indeed, transcription of the IGFBP-1 promoter in-
duced by Foxo1 was markedly increased when p300
was overexpressed (12.5  0.9-fold, mean  SE, n 
7) (Fig. 5A). By contrast, overexpression of p300-DY
failed to enhance transactivation of the IGFBP-1 pro-
moter by Foxo1 (Fig. 5B). These results suggest that
the acetyltransferase activity of p300 is required not
only for acetylation of Foxo1 but also for the stimula-
tion of Foxo1-induced transcription, further supporting
the hypothesis that Foxo1 acetylation may play a crit-
ical role in the stimulation of Foxo1 transcriptional
activity by p300.
Insulin Potently Enhances the Acetylation of
Foxo1 by p300
Insulin is the major negative regulator of Foxo1-stim-
ulated transcription. This is thought to occur predom-
Fig. 1. Foxo1 Is Acetylated in Vivo by Wild-Type p300 But Not by an Acetylase-Deficient p300 Mutant
HEK-293T (A) and H4IIE (B) cells were cotransfected with expression vector for myc-tagged Foxo1 together with FLAG-tagged
p300 or the empty expression vector as indicated. Foxo1 proteins were immunoprecipitated (IP) with anti-myc antibody followed
by immunoblotting (WB) with antibody to acetyl-lysine. The expression levels of Foxo1 protein and p300 were examined by
immunoblotting total cellular lysates with anti-Foxo1 and anti-FLAG antibodies, respectively. Representative examples of three
to five independent experiments are shown. The acetylation signal is weaker in H4IIE cells than in HEK-293T cells because of a
lower efficiency of transfection. C, HEK-293T cells were cotransfected with myc-tagged Foxo1 and FLAG-tagged wild-type p300
or the acetylase-deficient myc-tagged p300 mutant (p300-DY). Immunoprecipitation with anti-myc antibody was followed by
immunoblotting with anti-acetyl-lysine antibody as indicated. The level of Foxo1 protein in cells cotransfected with empty vector
control in this experiment was too high to be able to appreciate a further increase in abundance in the presence of p300.
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inantly through phosphorylation of its three PKB/Akt
consensus sites (Thr24, Ser253, and Ser316) (22, 23, 52).
To begin exploring whether insulin might also regulate
Foxo1 transcriptional activity through another post-
translational modification such as acetylation, we ex-
amined the effect of insulin on p300-induced acetyla-
tion of Foxo1 (Fig. 6). Surprisingly, addition of insulin to
p300-expressing cells led to a rapid and transient
increase of acetylated Foxo1 (Fig. 6A). Although the
acetyl-lysine signal was maximal at 5 min in the ex-
periment shown, the peak of acetylation varied from
1–10 min in different experiments. As seen in Fig. 6B,
the maximal enhancement of p300-dependent acety-
lation of Foxo1 by insulin was 5.9  1.1 (mean  SE,
n  3). Foxo1 acetylation was not observed with the
acetylase-deficient p300-DY even in the presence of
insulin (Fig. 6C), excluding the possibility that after
insulin treatment p300-DY might have recruited an-
other acetyltransferase protein that could acetylate the
forkhead protein.
The observation that Foxo1 acetylation is a transient
event after insulin treatment suggested that after an
initial increase, the abundance of acetylated Foxo1
might decrease due to the induction of a deacetylase.
In fact, treatment with the histone deacetylase inhibitor
trichostatin A (TSA) dramatically increased the levels
of acetylated Foxo1 in HEK-293T cells (Fig. 6D), al-
though the Foxo1 protein levels were identical in un-
treated and treated cells. Identical results were ob-
tained when another deacetylase inhibitor, sodium
butyrate, was used (data not shown). The increased
levels of acetylated Foxo1 after TSA treatment also
were seen in cells that had not been treated with
insulin, suggesting that the deacetylase activity may
be constitutive and that the enhancement of Foxo1
acetylation by insulin most likely results from in-
creased acetylase activity.
Phosphorylation of the PKB/Akt Sites Is Required
for Insulin-Enhanced Acetylation of Foxo1
We next determined whether phosphorylation of the
PKB/Akt sites in Foxo1 might be required for its acet-
ylation. Wild-type Foxo1 1–652 and a Foxo1 mutant in
which the three PKB/Akt phosphorylation sites weremu-
tated to alanine [Foxo1/Thr24Ala/Ser253Ala/Ser316Ala
(Foxo1/AAA)] were transfected into HEK-293T cells to-
gether with p300. As shown in Fig. 7, in the absence of
insulin, Foxo1/AAA was acetylated to a greater extent
than wild-type Foxo1, suggesting that basal phosphor-
ylation of the three PKB/Akt sites might have inhibited
acetylation as proposed for FOXO3a (37). Moreover, in
contrast to wild-type Foxo1, acetylation of Foxo1/AAA
decreased during incubation with insulin, indicating that
phosphorylation of the PKB/Akt sitesmay be required for
insulin-induced acetylation.
Effect of p300 and Acetylation on Insulin
Inhibition of Foxo1-Mediated Transcription
Because p300 overexpression markedly stimulated
Foxo1-induced transcription in the absence of insulin,
we next examined the effect of the coactivator on
insulin inhibition of transactivation stimulated by
Foxo1 (Fig. 8). As we previously reported (19, 20),
insulin potently inhibited transactivation by wild-type
Foxo1 (Fig. 8). Even though cotransfection with p300
stimulated Foxo1 acetylation, it did not affect insulin
inhibition of Foxo1-stimulated transactivation of the
IGFBP-1 promoter. Overexpression of p300 caused a
smaller increase in Foxo1/AAA transcriptional activity
in the absence of insulin than is seen with wild-type
Foxo1 even though its acetylation was increased. Mu-
tation of the PKB/Akt sites or acetylation of additional
sites in Foxo1/AAAmay have limited the ability of p300
to enhance Foxo1/AAA-stimulated transcription. Insu-
lin inhibited Foxo1/AAA transcriptional activity to only
a small extent in the presence or absence of p300,
Fig. 2. p300 Stabilizes Foxo1 Protein Levels in an Acetyl-
transferase-Independent Manner
HEK-293T cells were transfected with Foxo1 together with
empty vector and either wild-type p300 (A) or the acetylase-
deficient mutant p300-DY (B). Twenty-four hours after trans-
fection, cycloheximide (10 g/ml) was added and the abun-
dance of Foxo1 in cell lysates was determined at the
indicated times by Western blotting. The intensity of the
Foxo1 protein band was quantified using NIH imaging soft-
ware. The percent of Foxo1 proteins remaining is plotted;
levels at 0 h were taken as 100%. The graphs shown are
representative of three independent experiments. Although
our results indicate that overexpression of either p300 or
p300-DY stabilizes expressed-Foxo1, the higher abundance
of the exogenously expressed proteins may have contributed
to the slower clearance.
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Fig. 3. Foxo1 Interacts with p300 in Vitro and in Vivo
A,GST pull-down assay. FLAG-taggedwild-type p300was transiently expressed in HEK-293T cells. Cellular lysatesweremixedwith
GST-FOXO1 or GST bound beads, and a GST pull-down assay was performed. Reaction products were resolved on SDS-PAGE and
bound p300was visualized by immunoblottingwith anti-FLAG antibody. B, Immunoprecipitation. Nuclear extracts fromHEK-293T cells
were immunoprecipitated with anti-Foxo1 or anti-p300 antibodies. The precipitated proteins were analyzed by Western blotting using
anti-Foxo1 antibody. C and D, Immunoprecipitation. HEK-293T cells were transfected with FLAG-tagged wild-type p300 (C) or
p300-DY (D), together with myc-tagged full-length Foxo1 or GFP-tagged Foxo1 208–652 expression vectors as indicated. Nuclear
extracts were prepared and immunoprecipitated with anti-myc or anti-GFP antibodies, or control IgG from nonimmune mouse serum
(IgG). The precipitated proteins were analyzed by Western blotting using anti-FLAG or anti-myc antibody. A representative experiment
is shown.
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confirming that phosphorylation was the predominant
determinant of insulin inhibition of Foxo1 transcrip-
tional activity.
Effect of p300 on the Subcellular Localization of
Foxo1 in the Presence and Absence of Insulin
Nuclear exclusion of Foxo1 is thought to play a major
role in insulin-induced inhibition of transcription (23,
32). We examined whether alterations in the subcellu-
lar localization of Foxo1 proteins in H4IIE cells could
account for the enhancement of basal Foxo1-stimu-
lated transcription by p300. As previously reported
(20, 23, 32), indirect immunofluorescence demon-
strated the predominant nuclear localization of Foxo1
under basal conditions, and its subsequent redistribu-
tion to the cytoplasm after insulin stimulation (Fig. 9).
Overexpression of p300 led to an even greater nuclear
localization of Foxo1 but did not prevent its translo-
cation to the cytoplasm in response to insulin. An
identical result was obtained when the p300-DY mu-
tant was overexpressed (data not shown), indicating
that acetylation is not required for Foxo1 redistribution
to the cytoplasm. Altogether, these results indicate
that the small increase in nuclear localization of Foxo1
after p300 overexpression in the absence of insulin is
not sufficient to account for the marked stimulation of
Foxo1-induced transcription by p300 under basal
conditions.
DISCUSSION
Posttranslational modification of transcription factors
is a prominent mechanism of transcription regulation
(53–55). Although the role of phosphorylation in the
regulation of Foxo1 transcriptional activity has been
extensively documented, the possible contribution of
Fig. 4. Foxo1 Is a Target of Acetylation by p300
A, Autoradiogram of the in vitro acetylation assay. Recombinant GST-Foxo1 1–207 (lane 3), GST-Foxo1 1–652 (lanes 4–5) or
GST protein alone (lane 2) were incubated with 0.8 g of baculovirus-expressed His6-tagged full-length p300 in the presence of
[1-14C]acetyl-CoA for 1 h at 30 C. Core histones (Histones) (lane 1) were used as a positive control. Reaction products were
separated by SDS-PAGE and processed for autoradiography. The labeled band of acetylated GST-Foxo1 1–652 protein after a
12-h exposure is indicated. A representative experiment is shown. B, Coomassie blue staining of SDS-PAGE separation of
purified recombinant proteins used in the in vitro acetylation assay. The top part of the gel with the autoacetylated full-length p300
was cut off. The numbers on the left indicate the migration positions of molecular mass markers (in kilodaltons). The asterisks
indicate the positions of intact GST-Foxo1 1–652 in the right two lanes and histones in lane 1.
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other posttranslational modifications has only recently
been considered. In this report, we show that overex-
pression of the coactivator p300 potently stimulates
Foxo1-induced IGFBP-1 transcription and directly
acetylates Foxo1 protein in vivo and in vitro. The
acetyltransferase activity of p300 is required for both
effects. Although the precise role of Foxo1 acetylation
remains to be elucidated, our results suggest that
acetylation of Foxo1 by p300 may be responsible, at
least in part, for its increased transactivating activity.
Nasrin et al. (42) were the first to provide suggestive
evidence that CBP might regulate FOXO1-induced
IGFBP-1 transcription. They reported that the adeno-
viral protein E1a inhibited transcription stimulated by
Daf-16 or FOXO1, possibly by competitively inhibiting
the binding of the transcription factors to the C/H3
domain of p300/CBP (44). The argument was not con-
clusive, however, because E1A also can inhibit tran-
scription by mechanisms that do not involve the two
coactivators (51). We now demonstrate that overex-
pression of p300 potently increases Foxo1-stimulated
IGFBP-1 transcription approximately 12-fold.
The acetyltransferase activity of p300 is required for
p300 enhancement of Foxo1-mediated IGFBP-1 tran-
scription. No stimulation of IGFBP-1 transcription was
seen when a p300 mutant deficient in acetyltrans-
ferase activity was used, consistent with what has
been reported for other transcription factors: erythroid
Kruppel-like factor (56), HNF-4 (57), c-myc (58), and
sterol regulatory element-binding protein 1 (59). Our
results, however, contrast with the increased stimula-
tion of Foxo4 transcriptional activity observed after
cotransfection of an acetylase-deficient mutant of
CBP recently reported by Fukuoka et al. (38).
As we demonstrate in this report, Foxo1 is acety-
lated by p300 in vivo and by recombinant p300 in vitro.
Although p300 might acetylate Foxo1 indirectly, by
recruiting other acetyltransferases such as p300/CBP-
associated factor (P/CAF) (60) or steroid receptor co-
activator-1 (SRC-1) (61), which have been shown to
bind to FOXO1 (42), our in vitro results demonstrate
that Foxo1 can be directly acetylated by p300. We
show that p300 specifically binds to and acetylates the
carboxyl-terminal region of Foxo1 that contains the
transactivation domain (Foxo1 208–652) but does not
acetylate the amino-terminal protein fragment (Foxo1
1–207). Consistent with our results, Fukuoka et al. (38)
identified three lysine residues in the same region of
Foxo4 that were acetylated by CBP, and Brunet et al.
(39) demonstrated that five carboxyl-terminal lysines in
FOXO3a were acetylated in response to oxidative
stress. All five of the FOXO3a acetylation sites and two
of the three sites in Foxo4 are conserved in Foxo1. In
fact, the residue corresponding to Lys242 of Foxo1 is
acetylated in both FOXO3a and Foxo4.
The fact that the acetyltransferase activity of p300 is
required for both the enhancement of Foxo1-stimu-
lated transcription and for the acetylation of Foxo1
suggests that acetylation of Foxo1 by p300 per semay
be responsible for its potentiation of Foxo1-stimulated
transcription, although acetylation of histones cannot
be excluded. Indeed, a direct relationship between
acetylation of specific lysines on transcription factors
and increased transcriptional activity (48) has been
documented for several transcription factors, includ-
ing p53 (62), GATA-1 (63, 64), Drosophila T-cell fac-
tor-1 (65), erythroid Kruppel-like factor (56, 66), HIV-1
Tat protein (67), c-Myb (68), MyoD (69), the estrogen
receptor (70), the androgen receptor (71), and HNF-4
(57).
Acetylation of other members of the FOXO subfam-
ily by p300/CBP has had variable effects on their tran-
scriptional activity. Motta et al. (40) showed that over-
expression of p300 increased FOXO3a transcriptional
activity toward the Bim promoter, and that the in-
creased activity was inhibited by the NAD-dependent
deacetylase SIRT1. Because SIRT1 can deacetylate
both p300 and FOXO3a, however, the inhibition of
p300-enhanced transcription could result from
deacetylation of either p300 or Foxo3a. By contrast,
acetylation of Foxo4 by CBP appears to inhibit its
transcriptional activity (38). Van der Horst et al. (41)
confirmed that CBP overexpression decreased
FOXO4 induction of p27. These differences are un-
doubtedly functionally significant. Although many ac-
tions of the FOXO transcription factors are inter-
changeable, it is now appreciated that they exhibit
specific nonredundant functions during development
(72). Foxo1 null mice are embryonic lethals due to
Fig. 5. p300 Stimulates the Transcriptional Activity of Full-
Length Foxo1 in an Acetyltransferase-Dependent Manner
A, H4IIE cells were transfected with the expression vector
for p300, pCMV5/Foxo1, and the IGFBP-1 luciferase reporter
plasmid. The relative luciferase activity of cells transfected
with Foxo1 proteins in the absence of p300 was taken as
100%. Results are displayed as the mean  SE of seven
independent experiments. B, H4IIE cells were transiently
transfected with the IGFBP-1 luciferase reporter plasmid and
pCMV5/Foxo1 together with either wild-type p300 (wt), mu-
tant p300-DY (DY) or the empty expression vector (Control).
The mean  SE of three independent experiments is shown.
For unexplained reasons, the stimulation of Foxo1-stimulated
transcription by wild-type p300 was lower in these experi-
ments than in the experiments shown in panel (A).
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Fig. 6. Stimulation of p300-Dependent Foxo1 Acetylation by Insulin
A, Myc-tagged Foxo1 was expressed in HEK-293T cells together with FLAG-tagged p300 or empty vector. After 24 h, cells
were switched to serum-free medium overnight before incubation with recombinant human insulin (0.25 g/ml) for the indicated
times. Foxo1 proteins were immunoprecipitated with anti-myc antibody followed by Western blotting with antibody to acetyl-
lysine. A representative experiment is shown. B, Quantification of the maximal enhancement of p300-dependent acetylation of
Foxo1 by insulin. Foxo1 acetylation in the absence of insulin in the same experiment was taken as 1. Results are displayed as
the mean  SE (n  3). C, HEK-293T cells were transiently transfected with myc-tagged Foxo1 and FLAG-tagged p300 or
myc-p300-DY mutant and treated with insulin as described in panel (A). D, HEK-293T cells overexpressing myc-tagged Foxo1
and FLAG-tagged p300 were either untreated or treated with insulin (0.25 g/ml) in the presence (TSA) or absence of TSA (0.4
M), and harvested at the indicated time points. The immunoprecipitates were subjected to Western blotting with anti-acetyl-
lysine antibody. The levels of the different tagged proteins were examined in total cell lysates by immunoblot analysis with the
antibodies to myc and FLAG.
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Fig. 7. Phosphorylation of the PKB/Akt Sites Is Required for Insulin-Induced Acetylation of Foxo1 by p300
A, HEK-293T cells were transfected with FLAG-tagged p300 along with myc-tagged Foxo1 wild-type (wt) or Foxo1/Thr24Ala/
Ser253Ala/Ser316Ala (AAA). Cells were treated with insulin (0.25 g/ml) for the indicated times. Foxo1 proteins were immunopre-
cipitated with anti-myc antibody followed by immunoblotting with anti-acetyl-lysine antibody. The position of Foxo1 and the heavy
chain of the immunoprecipitating antibody are indicated by an arrowhead and arrow, respectively. The membrane was stripped
and reprobed with the anti-FOXO1-pThr24 and anti-FOXO1-pSer253 antibodies. The expression levels of Foxo1 proteins and p300
were assessed by immunoblotting total cellular lysates with anti-Foxo1 and anti-FLAG antibodies, respectively. The weaker signal
with Foxo1/AAA compared with wild-type Foxo1 could represent lower transfection efficiency or decreased immunoreactivity. B,
Quantification of the p300-dependent acetylation of wild-type Foxo1 and Foxo1/AAA by insulin. Wild-type Foxo1 acetylation in
the absence of insulin was taken as 100%. Results are displayed as the mean  SE (n  3).
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defective development of the vascular system,
whereas Foxo4 null mice are viable and have no gross
defects. Structural heterogeneity of the FOXO proteins
may lead to acetylation of different sites by p300/CBP
with different functional consequences. Our results
demonstrating that p300 binds to the carboxyl-termi-
nal region of Foxo1 are in contrast to a recent study
showing that p300 interacts with the first 52 amino
acids of FOXO3a (37), suggesting that p300 may rec-
ognize multiple sites in FOXO proteins. It remains to be
determined whether the divergent effects of p300/
CBP on the transcriptional activity of acetylated Foxo1
and Foxo4 result from the acetylation of different sites
or other structural differences that might affect pro-
moter selectivity.
Acetylation of transcription factors can regulate their
transcriptional activity by altering their DNA binding
activity and interaction with transcription-regulatory
proteins, as well as their stability and subcellular lo-
calization. Our analysis reveals that acetylation of
Foxo1 by p300 does not alter its stability or localiza-
tion. Exogenous expression of wild-type p300 but also
the acetyltransferase-defective p300-DY mutant in-
creased the half-life of Foxo1 protein in cells, indicat-
ing that acetylation itself is not critical for stabilization
of the forkhead protein. Furthermore, stabilization of
Foxo1 by p300 is unique in that it does not require its
acetylation, in contrast to other transcription factors
such as p53 (73–75), HNF-4 (57), Smad7 (76), and
sterol regulatory element-binding protein 1 (59), for
Fig. 9. Subcellular Localization of Foxo1 in Hepatocytes
Transfected with p300
Myc-tagged Foxo1 was expressed in subconfluent H4IIE
cells, together with FLAG-tagged p300 or the empty vector
control. Twenty-four hours after transfection, cells were
transferred to serum-free medium for an additional 16 h be-
fore the addition of insulin (1 g/ml), fixed, and analyzed by
immunofluorescence for nuclear staining (DAPI, bottom) and
myc expression using specific monoclonal antibody and FITC
(fluorescein isothiocyanate)-conjugated antimouse IgG (top).
Shown are representative images of six independent exper-
iments with similar results.
Fig. 8. Insulin Inhibition of Foxo1-Mediated Transcription Is Decreased by Mutation of the Three PKB/Akt Sites But Not by
Cotransfection with p300
H4IIE cells were transiently transfected with the IGFBP-1 luciferase reporter plasmid and p300 or the corresponding empty
vector control, together with expression vectors encoding wild-type Foxo1 or Foxo1/Thr24Ala/Ser253Ala/Ser316Ala (Foxo1/AAA).
Two independent Foxo1/AAA clones were used. After 48 h, half of the cells were treated with recombinant human insulin (0.25
g/ml). Relative luciferase activity is plotted. The activity with Foxo1 in the absence of p300 and insulin is taken as 100%. The
mean  SD of two experiments is plotted.
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which stabilization has been demonstrated to be as-
sociated with their acetylation. Similarly, overexpres-
sion of p300 has only limited effects on the subcellular
distribution of Foxo1 that are unlikely to account for
the marked stimulation of Foxo1-induced transcrip-
tion. This differs from the marked effects of acetylation
of HNF-4 preventing its nuclear export (57) or acety-
lation of the RelA subunit of the nuclear factor-B
heterodimer, preventing it from being sequestered in
the cytoplasm (77). The enhancement of Foxo1-in-
duced transcription by p300 might occur because
acetylation increases DNA binding as reported for the
transcription factors p53 (62, 78), GATA-1 (63), E2F-1
(79), HNF-4 (57), c-Myb (68), RelA (77), and E2F-1,2,3
(80), or by facilitating the recruitment of coactivators to
the promoter in vivo (81).
Insulin is the major negative regulator of Foxo1-
stimulated transcription. We examined whether insulin
regulated Foxo1 acetylation and, if so, how this might
affect its transcriptional activity. We observed that in-
sulin potently enhances Foxo1 acetylation by p300.
The increase was transient, however, suggesting the
existence of negative regulators of Foxo1 acetylation.
In support of this hypothesis, we showed that the
abundance of acetylated Foxo1 is considerably in-
creased when deacetylases are inhibited whether or
not insulin is present, suggesting that deacetylase ac-
tivity is constitutive and that insulin acts instead by
stimulating p300 acetyltransferase activity. Moreover,
as in the absence of insulin, acetylation was not ob-
served with p300-DY, indicating that insulin treatment
did not lead to the recruitment of another acetyltrans-
ferase that could acetylate the Forkhead protein.
Although insulin and the cytokine erythropoietin
both activate PKB/Akt and stimulate phosphorylation
of FOXO proteins, insulin enhances p300-stimulated
acetylation of Foxo1, whereas erythropoietin inhibited
p300 binding to and acetylation of FOXO3a (37). Mah-
mud et al. (37) concluded that dephosphorylation of
FOXO3a was a prerequisite for acetylation. By con-
trast, we observed that insulin stimulated the phos-
phorylation and acetylation of wild-type Foxo1, and
that insulin-induced acetylation was reduced in
Foxo1/AAA in which the PKB/Akt sites were mutated,
indicating that insulin-stimulated phosphorylation of
the PKB/Akt sites did not inhibit and probably pro-
moted Foxo1 acetylation. Phosphorylation was not
required for basal acetylation, however, because acet-
ylation was increased in Foxo1/AAA in the absence of
insulin.
Although insulin increases the acetylation of Foxo1
by p300, insulin’s ability to inhibit Foxo1-stimulated
transcription is unchanged by p300 overexpression
and acetylation (Fig. 10). Insulin-induced phosphory-
lation of the three PKB/Akt sites in Foxo1 leading to its
export from the nucleus remains the predominant de-
terminant of Foxo1 transcriptional activity and is un-
affected by increased acetylation. A similar dissocia-
tion of insulin’s effect on p300-induced acetylation
and its effects on Foxo1 transcriptional activity is seen
in Foxo1/AAA in which the three PKB/Akt sites have
been mutated. Insulin’s ability to inhibit Foxo1-stimu-
lated transcription is greatly reduced irrespective of
whether p300 is overexpressed or whether insulin de-
creases p300-induced acetylation in the mutant. Thus,
even though insulin regulates the level of acetylation of
Foxo1 and Foxo1/AAA by p300, the effects on Foxo1
acetylation do not significantly affect its ability to in-
hibit Foxo1 transcriptional activity. Insulin inhibition of
Foxo1-stimulated transcription is predominantly de-
termined by insulin-induced phosphorylation and the
resulting export of the transcription factor from the
nucleus and inhibition of Foxo1-stimulated transcrip-
tion, which are unaffected by p300 overexpression
and increased acetylation of Foxo1.
In summary, we have shown that Foxo1 and its
carboxyl-terminal protein fragment are targets of the
p300 acetyltransferase. p300 Binds to and acetylates
lysines located in the carboxyl-terminal region of
Foxo1. p300 Also functions as a coactivator and po-
tentiates Foxo1-induced transactivation in the ab-
sence of insulin. Our results suggest that direct acet-
ylation of Foxo1 by p300 may be responsible for p300
enhancement of Foxo1-stimulated transcription, al-
though acetylation of histones cannot be excluded.
The enhanced transcription may reflect increased
binding of acetylated Foxo1 to DNA motifs in the pro-
moter of target genes or interactions with coactivators
but does not appear to involve stabilization or en-
hanced nuclear localization of Foxo1. Acetylation of
Foxo1 by p300 is increased by insulin but, paradoxi-
cally, insulin inhibition of transcription still occurs in
the presence of p300. This most likely reflects the
preeminent role of phosphorylation in the inhibition of
Foxo1 transcriptional activity by insulin, although sec-
ondary effects of acetylation cannot be excluded.
MATERIALS AND METHODS
Materials
Sodium butyrate and cycloheximide were purchased from
Sigma (St. Louis, MO). Trichostatin A was obtained from Cell
Signaling Technology (Beverly, MA). Restriction enzymes
were purchased from Invitrogen (Life Technologies Inc.,
Carlsbad, CA). Taq polymerase was obtained from
PerkinElmer Life Sciences-Applied Biosystems (Foster City,
CA), and human recombinant insulin (Humulin U-100 regular)
was from Eli Lilly & Co. (Indianapolis, IN).
Cell Lines
H4IIE rat hepatoma cells and HEK-293T cells were grown as
monolayer cultures in low-glucose and high-glucose DMEM
(Life Technologies Inc.), respectively. Cells were grown at 37
C in the presence of 10% fetal bovine serum (HyClone Lab-
oratories, Logan, UT) and antibiotics (50 U/ml of penicillin and
50 g/ml of streptomycin) in a humidified atmosphere of 5%
CO2.
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Plasmid Constructs
The expression vector encoding pcdef3/FLAG-p300 was
kindly provided by Dr. D. M. Livingston (Dana-Farber Cancer
Institutes, Boston, MA). The pcDNA/myc-p300 acetylase-de-
ficient mutant, p300-DY (Lysine 1399 converted to tyrosine),
was a generous gift of Dr. T. P. Yao (Duke University) (50). The
expression vectors encoding pcdef3/E1A and mutant pc-
def3/E1a2–36 were graciously obtained from Dr. A. B. Rob-
erts [National Cancer Institute, National Institutes of Health
(NIH)]. The rat IGFBP-1 (p925GL3) and the pG5E1b promot-
er-luciferase reporter plasmids used for luciferase assays
were described previously (19, 20). pCMV5/c-Myc-Foxo1
1–652 and pCEF/GFP-Foxo1 208–652 were previously re-
ported (20).
Site-Directed Mutagenesis
Mutations were introduced using a PCR-based method
(QuikChange site-directed mutagenesis kit; Stratagene, La
Jolla, CA) following the manufacturer’s instructions. The three
PKB/Akt consensus phosphorylation sites Thr24, Ser253, and
Ser316 were mutated to alanine in pCMV5/c-Myc-Foxo1
1–652. Mutated oligonucleotides used for DNA amplification
are available on request. The sequence of all constructs was
confirmed by automated DNA sequencing using a rhodamine
fluorescent terminator sequencing kit (PerkinElmer Life Sci-
ences-Applied Biosystems).
Transient Transfection and Luciferase Assays
H4IIE cells were transfected as previously described (20)
using diethylaminoethyl-dextran (Amersham Pharmacia Bio-
tech, Piscataway, NJ). The luciferase and -galactosidase
assays were performed as described (20), cotransfecting
pRSV--galactosidase to allow for normalization of transfec-
tion efficiency. The total amount of transfected DNA was
standardized by addition of empty control vector as required.
Assays were performed in duplicate and are represented as
mean  SEM of at least three independent experiments.
Fig. 10. Schematic Diagram Summarizing the Effect of Acetylation and Phosphorylation on Foxo1-Stimulated IGFBP-1 Promoter
Activity
Wild-type Foxo1 (lines 1 and 2) and Foxo1/AAA (lines 3 and 4) were cotransfected with empty vector (lines 1 and 3) or p300
(lines 2 and 4). The effects of p300 and insulin on posttranslational modifications of Foxo1 (lysine acetylation and phosphorylation
of the three PKB/Akt sites) are indicated. Foxo1 transcriptional activity in the absence of insulin (p300/p300) is indicated by
solid arrows to the left. The effect of insulin on Foxo1 transcriptional activity (Insulin/Insulin) is indicated by solid arrows to the
right. In the absence of insulin, p300 stimulates acetylation of wild-type Foxo1 and, to a greater extent, Foxo1/AAA, suggesting
that basal phosphorylation of the PKB/Akt sites might inhibit acetylation. p300 markedly stimulates transcription of wild-type
Foxo1 and, to a lesser extent, Foxo1/AAA. Insulin stimulates the phosphorylation of the PKB/Akt sites in wild-type Foxo1 and
inhibits Foxo1 transcriptional activity. Although insulin stimulates the acetylation of wild-type Foxo1 by p300, it inhibits Foxo1
transcriptional activity to the same extent as in the absence of p300. The inability of insulin to inhibit Foxo1/AAA-stimulated
transcriptional activity is not affected by p300, even though insulin inhibits p300-induced acetylation of Foxo1/AAA. These results
indicate that insulin inhibition of Foxo1-stimulated transcription is predominantly determined by phosphorylation of the PKB/Akt
sites and is not significantly affected by the additional acetylation. Ac, Acetyl; S, serine; T, threonine; pS, phosphoserine; pT,
phosphothreonine.
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Expression and Purification of Foxo1 Proteins
The pGEX/Foxo1 1–207 construct was obtained by PCR
using the sense primer, 5-ATAGAATTCATGGCCGAG-
GCGCCCCAG-3 and the antisense primer 5-ATACTC-
GAGTTACTTCCAGCCCGCCGAGCT-3. The PCR frag-
ment was subcloned into the EcoRI-XhoI sites of pGEX-
4T-1 vector (Amersham Pharmacia Biotech). The pGEX/
Foxo1 1–652 construct was generated according to the
same procedure, using the sense primer 5-ATAGGATC-
CATGGCCGAGGCGCCCCAG-3 and the antisense primer
5-ATACTCGAGTTAGCCTGACACCCAGCTGTG-3, and
insertion of the PCR fragment into the BamHI-XhoI sites of
pGEX-4T-1 vector. GST fusion proteins were purified using
glutathione-Sepharose beads (Amersham Pharmacia Bio-
tech) following the manufacturer’s instructions.
In Vitro Acetylation Assay
Recombinant Foxo1 proteins were acetylated in vitro by
His6-tagged full-length p300 purified from baculovirus-in-
fected cells and generously provided by T. P. Yao and
C. H. Lai (Duke University). The acetylation reactions were
performed in a buffer containing 50 mM Tris base, pH 8.0;
0.1 mM EDTA; 1 mM dithiothreitol and 10% (vol/vol) glyc-
erol, supplemented with 0.8 g of His6-tagged full-length
p300 and substrate in the presence of 0.05 Ci of
[1-14C]acetyl-CoA (Amersham Pharmacia Biotech). Reac-
tions were performed at 30 C for 1 h and quenched with
Laemmli buffer. Reaction products were then subjected to
8–16% SDS-PAGE and analyzed by autoradiography, fol-
lowed by Coomassie blue staining. In addition, the acety-
lated proteins were spotted onto P81 phosphocellulose
filter paper and counted for 14C activity by liquid scintilla-
tion counting.
GST Pull-Down Assay
Lysates from HEK-293T cells transiently expressing FLAG-
tagged p300 were incubated with 3 g of GST-FOXO1
(Upstate Biotechnology, Lake Placid, NY) or GST. Binding
reactions mixtures were precipitated using glutathione-
Sepharose beads (Amersham Pharmacia Biotech). Bound
proteins were recovered from the beads by boiling the
beads in sample buffer and then resolved on SDS-PAGE.
Proteins were transferred to nitrocellulose membrane and
subjected to Western blot analysis with anti-FLAG anti-
body (Covance, Princeton, NJ).
Immunoprecipitation and Western Blot Analysis
HEK-293T and H4IIE cells were transfected using the
LipofectAMINE Plus reagent (Invitrogen) according to the
manufacturer’s instructions. Cells were switched to serum-
free medium overnight before incubation with recombinant
human insulin (0.25 g/ml) for the indicated times. Lysis
was performed in the presence of 5 mM sodium butyrate,
an inhibitor of protein deacetylases, using radioimmuno-
precipitation assay buffer [50 mM Tris-HCl (pH 7.2), 500 mM
NaCl, 10 mM MgCl2, 1% Triton X-100, 0.1% sodium dodecyl
sulfate, 0.5% sodium deoxycholate] containing 10 g/ml
aprotinin, 10 g/ml leupeptin and 1 mM phenylmethylsulfonyl
fluoride. Lysates were cleared by centrifugation and then
either resolved directly by SDS-PAGE and transferred onto
nitrocellulose membrane, and/or first immunoprecipitated
with anti-myc (9E10) or anti-GFP (green fluorescent protein)
antibodies (Covance). Western blots were detected using
anti-acetyl-lysine (4G12) (Upstate Biotechnology) antibody.
The expression level of Foxo1 and p300 constructs was
examined by immunoblotting analysis using anti-Foxo1 and
anti-p300 antibodies (Santa Cruz Biotechnology, Santa Cruz,
CA), respectively. Proteins were visualized with an enhanced
chemiluminescence detection system (Pierce, Rockford, IL).
Autoradiographs were scanned and the images analyzed
using the software program NIH image 1.62 (NIH, Bethesda,
MD). In addition, nuclear extracts from HEK-293T cells were
obtained using the nuclei EZ prep isolation buffer (Sigma) and
processed as described in Ref. 20.
Immunofluorescence
Immunofluorescence experiments were performed as de-
scribed previously (20). Briefly, H4IIE and HEK-293T cells
were transiently transfected with the LipofectAMINE Plus
reagent (Life Technologies). After 24 h, cells were serum-
starved overnight, before incubation with recombinant hu-
man insulin (1 g/ml) for 1 h at 37 C. Then, cells were fixed,
permeabilized and mounted with medium containing 4,6-
diamidino-2-phenylindole dihydrochloride (DAPI) (Vecta-
shield, Vector Labs, Burlingame, CA). Cells were visualized
using a fluorescence microscope.
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